Nebula Research & Development LLC Phathom Pharmaceuticals, Inc. Transaction History
Nebula Research & Development LLC
- $1.08 Trillion
- Q1 2025
A detailed history of Nebula Research & Development LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Nebula Research & Development LLC holds 28,821 shares of PHAT stock, worth $136,899. This represents 0.02% of its overall portfolio holdings.
Number of Shares
28,821
Previous 20,963
37.49%
Holding current value
$136,899
Previous $170 Million
6.16%
% of portfolio
0.02%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding PHAT
# of Institutions
152Shares Held
66.6MCall Options Held
94KPut Options Held
55.5K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$48 Million3.99% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$35.5 Million12.73% of portfolio
-
Jennison Associates LLC7.04MShares$33.5 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA3.65MShares$17.3 Million0.0% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$16.6 Million27.15% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $186M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...